emjreviews.com2d
New Decision Tool Improves COPD Outcomes While Reducing Antibiotics
Study reveals the Prospector calculator reduces antibiotic prescriptions in COPD exacerbations, improving outcomes and ...
Medpage Today on MSN2d
Genetic Risk Predictor Might Boost Detection of Undiagnosed COPD
If a threshold of 10% risk of COPD was used to make spirometry referrals, the addition of the polygenic risk score correctly ...
Verona Pharma stock target upgraded, retains buy on Q4 results
H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.
Verona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy Rating
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...
Verona Pharma price target raised to $60 from $42 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...
2minutemedicine.com4d
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...